Ultra-late response ( & gt; 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

ConclusionTwo-thirds of patients not responding to anti-CGRP mAbs ≤ 24 weeks do respond later, whilenon-responders ≤ 48 weeks are quite rare (8.7%). These findings suggest to rethink the duration of migraine prophylaxis and the definition of resistant and refractory migraine, currently based on the response after 2–3 months of treatment.

http://link.springer.com/10.1007/s00415-023-12103-4

Source: Journal of Neurology - January 17, 2024 Category: Neurology Source Type: research